Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone presented as a tablet for oral use. It is prescribed for the short‑term treatment of insomnia, helping adults who have difficulty falling asleep or maintaining sleep throughout the night and improve overall sleep quality.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with established quality assurance processes and regulatory compliance across EU and other markets.

Zopiclone is a cyclopyrrolone used to manage sleep disorders, primarily insomnia.

Insomnia: short‑term relief of difficulty falling asleep or staying asleep Sleep onset insomnia: helps initiate sleep within 30 minutes Sleep maintenance insomnia: reduces nighttime awakenings and promotes continuous sleep

Zopiclone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness - Dry mouth - Bitter taste - Dizziness

Serious or Rare Side Effects: - Complex sleep behaviours (e.g., sleepwalking, sleep‑driving) - Allergic reactions (rash, swelling, difficulty breathing) - Dependence or withdrawal symptoms on abrupt discontinuation

When prescribing Zopiclone, clinicians should consider several safety measures.

Assess patient history: evaluate for depression, respiratory disorders, or substance abuse Limit duration: prescribe for short‑term use, typically up to 2–4 weeks Avoid alcohol: concurrent use may enhance CNS depression Monitor elderly: increased sensitivity and fall risk Store at ambient temperature: keep tablets in original container, protect from moisture and light

Zopiclone can interact with other substances that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Alcohol: additive CNS depression leading to severe sedation - Opioids: heightened risk of respiratory depression and profound sedation - Other hypnotics (e.g., benzodiazepines): excessive sedation and impaired psychomotor function

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma levels of zopiclone - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy - Antidepressants (e.g., fluoxetine): potential additive CNS effects